BURLINGTON, Mass. , Jan. 22, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Christina Willwerth has been named Chief Strategy Officer. Ms. Willwerth joined Flexion in June 2009 , and she most recently served as the company’s Senior Vice President of Program
BURLINGTON, Mass. , Jan. 04, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to four new employees for an aggregate of 53,700 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with
Fourth-quarter 2018 revenue estimated to be approximately $9.5 million , an increase of 36% over the previous quarter Full-year 2018 revenue estimated to be approximately $22.5 million Flexion providing initial 2019 product revenue guidance of $65 to $80 million Conference call scheduled for
First patient enrolled in Phase 3 hip OA registration trial in late December 2018 ; trial expected to complete in 2020 Positive results from Phase 2 pharmacokinetics (PK) study of ZILRETTA in OA of shoulder and hip showed PK profiles consistent with previous studies in knee Additional Phase 2
BURLINGTON, Mass. , Dec. 20, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) will announce preliminary unaudited revenue for the fourth-quarter and full-year 2018 and provide revenue guidance for 2019 on Thursday, January 3, 2019 , after market close.
sNDA aims to revise the product label with new data indicating repeat administration of ZILRETTA was safe and well tolerated BURLINGTON, Mass. , Dec. 17, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced it submitted a supplemental new drug application (sNDA) to the
BURLINGTON, Mass. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to five new employees for an aggregate of 24,150 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with
BURLINGTON, Mass. , Nov. 16, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has been named one of the Top Places to Work in Massachusetts for the second consecutive year. The rankings are based on the results from an annual employee survey conducted by The
Company reported net ZILRETTA ® ( triamcinolone acetonide extended-release injectable suspension) sales of $7.0 million in Q3 representing 84% growth over Q2 Strong progress in Commercial activities: 79% of target accounts have purchased, or received samples of, ZILRETTA and 64% of ordering
BURLINGTON, Mass. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the Centers for Medicare and Medicaid Services (CMS) has issued a product-specific J code for ZILRETTA (triamcinolone acetonide extended-release injectable suspension).
